Cookies helfen uns bei der Bereitstellung unserer Dienste. Durch die Nutzung unserer Dienste erklären Sie sich damit einverstanden, dass wir Cookies setzen.
De En Es
Kundenservice: +49 (0) 551 - 547 24 0

Cuvillier Verlag

30 Jahre Kompetenz im wissenschaftlichen Publizieren
Internationaler Fachverlag für Wissenschaft und Wirtschaft

Cuvillier Verlag

Premiumpartner
De En Es
Titelbild-leitlinien
Systems metabolic engineering  of Escherichia coli for production of violacein and deoxyviolacein

Printausgabe
EUR 28,50

E-Book
EUR 19,95

Systems metabolic engineering of Escherichia coli for production of violacein and deoxyviolacein (Band 4)

André Luis Rodrigues (Autor)

Vorschau

Inhaltsverzeichnis, PDF (57 KB)
Leseprobe, PDF (210 KB)

ISBN-13 (Printausgabe) 9783954049608
ISBN-13 (E-Book) 9783736949607
Sprache Englisch
Seitenanzahl 128
Auflage 1. Aufl.
Buchreihe Hochschulschriften - Institut für Systembiotechnologie, Universität des Saarlandes
Band 4
Erscheinungsort Göttingen
Erscheinungsdatum 13.07.2015
Allgemeine Einordnung Dissertation
Fachbereiche Mikrobiologie und Biotechnologie
Schlagwörter violacein, deoxyviolacein, Escherichia coli, metabolic engineering
Beschreibung

Violacein and deoxyviolacein are promising therapeutics against pathogenic bacteria and viruses as well as tumor cells. In the present work, systems-wide metabolic engineering was applied to Escherichia coli for heterologous production of these high-value products. First, a high performance liquid chromatography method for accurate separation and quantification of violacein and deoxyviolacein was developed. Afterwards, a basic producer, E. coli dVio-1, that expressed the vioABCE cluster from Chromobacterium violaceum under control of the araBAD promoter and induction by L-arabinose, was constructed. Targeted intracellular metabolite analysis then identified bottlenecks in pathways that supply tryptophan, the major product building block of the natural products of interest. This was used for systems-wide engineering of serine, chorismate and tryptophan biosynthesis and the non-oxidative pentose-phosphate pathway, followed by elimination of L-arabinose catabolism. Transferred to a glycerol-based fed-batch process, E. coli dVio-8 surpassed the gram scale and produced 1.6 g L-1 deoxyviolacein (> 99.5% purity). The created chassis of a high-flux tryptophan pathway was complemented by genomic integration of the vioD gene of Janthinobacterium lividum, which enabled exclusive production of violacein (710 mg L-1 with 99.8% purity). This demonstrates the potential of E. coli as a platform for production of tryptophan based therapeutics.